US Patent Issued to C4 Therapeutics on Sept. 8 for "Tricyclic ligands for degradation of IKZF2 or IKZF4" (Massachusetts Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,193, issued on Sept. 8, was assigned to C4 Therapeutics Inc. (Watertown, Mass.).

"Tricyclic ligands for degradation of IKZF2 or IKZF4" was invented by Christopher G. Nasveschuk (Stoneham, Mass.), James A Henderson (Weston, Mass.), Moses Moustakim (Cambridge, Mass.), Andrew Charles Good (Watertown, Mass.) and David Proia (Newton, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Tricyclic compounds that degrade IKZF2 and/or IKZF4 are provided for medical therapy, including abnormal cellular proliferation, including cancer, inflammatory disorders, neurodegenerative disorders or autoimmune disorders."

The patent was filed on April 14, 2023, under A...